Prader-Willi syndrome Therapeutics Market to grow with 4.6% CAGR by 2024

October 25, 2019


According to the new research report available at MarketStudyReport.com under the title ‘Global Prader-Willi Syndrome (PWS) Therapeutics Market: Sizing, Prevalence, Pipeline Analysis (2019 Edition): Opportunities and Forecast (2019-2024)’, the worldwide prader-willi syndrome therapeutics market is presumed to expand with a growth rate of 4.6% by the year 2024.
 

Prader-willi syndrome (PWS) is a genetic disorder, which may cause problems in physical growth, eating disorders, and intellectual disability. This occurs owing to changes in chromosome 15, which is accountable for regulating the gene expression. Obesity and stunted growth are the main symptoms of the ailment.
 

Increasing instances of the ailment among the global population and its diagnosis are the major factors augmenting the Prader-willi syndrome therapeutics market. Widespread and rising coverage of human growth hormone therapy cost, increasing involvement of government with introduction of favorable policies, and rising awareness about the disorder, coupled with adoption of novel therapies are further fueling the market growth. However, hesitation towards making large investments for research & development of PWS medicines among the drug manufacturers is the main restraint hampering the industrial growth.
 

The report provides strategic recommendations, such as investment in somatropin biosimilar and combination therapy, for market expansion. It offers a comprehensive insight about the trends, drivers, challenges, and opportunities impacting the market growth.
 

Request sample copy of this Report@ https://www.marketstudyreport.com/request-a-sample/2237736/
 

In terms of pipeline analysis type, PWS therapeutics market is categorized as levolitide (millendo therapeutics), DCCR (soleno therapeutics), and tesomet (saniona).
 

Based on the regional outlook, the global prader-willi syndrome therapeutics market is divided into three major regions which are United States, Europe, and Japan. Furthermore, United States is presumed to dominate the PWS therapeutics market over the analysis period, owing to advanced medical technology and increased health consciousness among people across the region.
 

The prominent companies operating in prader-willi syndrome therapeutics market include Pfizer, Saniona, Novartis, Soleno Therapeutics, and Novo Nordisk.


Frequently Asked Questions (FAQ) :

Increasing instances of the ailment among the global population and its diagnosis are the major factors augmenting the prader-willi syndrome (PWS) therapeutics market. Widespread and rising coverage of human growth hormone therapy cost, increasing involvement of government with introduction of favorable policies, and rising awareness about the disorder, coupled with adoption of novel therapies are further fueling the market growth.
Pipeline analysis is gaining momentum in prader-willi syndrome (PWS) therapeutics market, thereby driving market growth. These PWS therapeutics are Levolitide by Millendo Therapeutics, DCCR by Soleno Therapeutics, and Tesomet by Saniona.
United States is presumed to dominate the prader-willi syndrome (PWS) therapeutics market in the forthcoming years, owing to advanced medical technology and increased health consciousness among people across the region.
The prominent companies operating in prader-willi syndrome (PWS) therapeutics market include Pfizer, Saniona, Novartis, Soleno Therapeutics, and Novo Nordisk.